All In Biotech

Drug Trial Radar · NCT04457596

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,056 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,056

Actual

Start

Mar 2, 2021

Primary completion

Jan 31, 2028

Study completion May 31, 2035

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); Seagen Inc.
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib is in a class of medications called kinase inhibitors. It blocks HER2, which may help keep cancer cells from growing and may kill them. Giving T-DM1 in combination with tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.

Conditions

  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • HER2 Positive Breast Carcinoma
  • Invasive Breast Carcinoma
  • Multifocal Breast Carcinoma
  • Synchronous Bilateral Breast Carcinoma
  • Anatomic Stage I Breast Cancer AJCC v8

Interventions

  • Trastuzumab EmtansineBiological

    Given IV

  • Placebo AdministrationDrug

    Given PO

  • TucatinibDrug

    Given PO

  • Questionnaire AdministrationOther

    Ancillary studies

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified invasive disease-free survival (iDFS)Time frame: From randomization to one of the following events: invasive local, regional or distant recurrence, invasive contralateral breast cancer or death from any cause, assessed up to 10 years

Locations

1,176 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Thomas Hospital

    Fairhope, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Banner-University Medical Center Phoenix

    Phoenix, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • UCSF Cancer Center - Berkeley

    Berkeley, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Mercy Cancer Center - Carmichael

    Carmichael, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Community Cancer Institute

    Clovis, California

  • John Muir Medical Center-Concord

    Concord, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • Sutter Davis Hospital

    Davis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Kaiser Permanente Dublin

    Dublin, California

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California

Showing 40 of 1,176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.